Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Rahma received his medical degree from University of Damascus in 1998. He completed his residency in Internal Medicine at East Carolina University followed by Geriatrics Fellowship at University of Hawaii. Dr. Rahma joined the National Cancer Institute (NCI) as an Immunotherapy Research Fellow in the Vaccine Branch in 2009 and completed a Fellowship in Medical Oncology in 2013 specializing in Cancer Immunotherapy and Gastrointestinal (GI) Oncology. While at NCI, his efforts led to the development of many clinical studies investigating immunotherapy in GI malignancies.
Prior to joining Dana-Farber Cancer Institute, Dr. Rahma was the co-leader of the Hepatobiliary and Pancreatic Cancer Program at University of Virginia where he led translational research efforts as the Principal Investigator of many clinical trials. Dr. Rahma joined the Center for Immuno-Oncology at Dana-Farber to be part of national and international efforts to advance the field of Cancer Immunotherapy. He is currently the chair of two investigator-initiated clinical trials using a novel combination of immune checkpoint inhibitor (anti-PD-1) and neoadjuvant chemoradiation in pancreatic and rectal cancer. During this exciting era of cancer immunotherapy and in collaboration with other investigators, Dr. Rahma will be investigating the combinations of variety of novel immunotherapeutic agents in multiple tumor types and working on identifying biomarkers that could determine clinical response.
Dana-Farber Cancer Institute450 Brookline AvenueBoston MA, 02215Get Directions